Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid
- PMID: 2243354
Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid
Abstract
Coadministration of polyaspartic acid protects against functional and pathological signs of gentamicin-induced nephrotoxicity in rats without reduction of drug accumulation in renal cortex (Williams et al., J. Pharmacol. Exp. Ther. 237: 919-925, 1986; Gilbert et al., J. Infect. Dis. 159: 945-953, 1989). We have assessed the influence of polyaspartic acid on the early alterations induced in kidney cortex by gentamicin, namely the lysosomal phospholipidosis and the increase in cell turnover. We used an infused rat model in which animals received a total dose of 100 mg/kg of gentamicin over 12 hr. Renal cortex was examined 2 hr (day 0) and 48 hr (day 2) after treatment. All animals received an injection of [3H]thymidine (200 microCi i.p.) before sacrifice. Coadministration of polyaspartic acid (drug-polypeptide mass ratio 1:2.5) did not modify the drug serum levels, as recorded during or shortly after the infusion. Yet, it was associated with 1) an increased (approximately 35%) drug cortical content at day 0; 2) a significant protection against both biochemical (decrease of sphingomyelinase activity at day 0; increase of lipid phosphorus content at day 2) and morphological (enlargement of lysosomes and deposition of myeloid bodies at day 2) signs of lysosomal phospholipidosis in proximal tubular cells; and 3) an almost complete protection against increased cell turnover (mostly in proximal tubules) in cortex at day 2, as assessed by the measurement of [3H]thymidine incorporation into DNA and the enumeration of S-phase cells after histoautoradiography. In addition, morphological studies revealed a larger number of apical vacuoles in proximal tubular cells of animals receiving polyaspartic acid alone (but not in combination with gentamicin), and the deposition of osmiophilic, homogenous material in the lysosomes of animals receiving the combination of gentamicin and polyaspartic acid. Together with the results reported in two companion papers (Kishore et al., J. Pharmacol. Exp. Ther. 867-874, and 875-885, 1990), these results provide evidence that protection afforded by polyaspartic acid extends to the earliest cellular alterations described in kidney for gentamicin, namely the lysosomal phospholipidosis, suggesting that this protecting agent exerts blocking effect from this step in the cascade of events relating drug cortical accumulation to renal toxicity.
Similar articles
-
Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro.J Pharmacol Exp Ther. 1990 Nov;255(2):867-74. J Pharmacol Exp Ther. 1990. PMID: 2243355
-
Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids.J Pharmacol Exp Ther. 1990 Nov;255(2):875-85. J Pharmacol Exp Ther. 1990. PMID: 1700819
-
Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats.J Pharmacol Exp Ther. 1992 Jul;262(1):424-32. J Pharmacol Exp Ther. 1992. PMID: 1378098
-
Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity.Ren Fail. 1992;14(3):351-7. doi: 10.3109/08860229209106642. Ren Fail. 1992. PMID: 1509168 Review.
-
An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin.Toxicol Sci. 2011 Feb;119(2):245-56. doi: 10.1093/toxsci/kfq267. Epub 2010 Sep 9. Toxicol Sci. 2011. PMID: 20829429 Review.
Cited by
-
Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury.Kidney Int. 2014 Mar;85(3):611-23. doi: 10.1038/ki.2013.462. Epub 2013 Dec 4. Kidney Int. 2014. PMID: 24304883 Free PMC article.
-
Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.Antimicrob Agents Chemother. 1997 Jun;41(6):1237-45. doi: 10.1128/AAC.41.6.1237. Antimicrob Agents Chemother. 1997. PMID: 9174177 Free PMC article.
-
Comparative effect of olive oil and fish oil supplementation in combating gentamicin induced nephrotoxicity in rats.Indian J Clin Biochem. 2005 Jan;20(1):109-14. doi: 10.1007/BF02893053. Indian J Clin Biochem. 2005. PMID: 23105505 Free PMC article.
-
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.J Mol Med (Berl). 2006 Jul;84(7):573-82. doi: 10.1007/s00109-006-0045-5. Epub 2006 Mar 16. J Mol Med (Berl). 2006. PMID: 16541275
-
When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.Medchemcomm. 2014 Aug 1;5(8):1092-1105. doi: 10.1039/C4MD00081A. Medchemcomm. 2014. PMID: 25147726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources